NCT03394365 2026-02-20
ALLELE
Pierre Fabre Medicament
Phase 3 Recruiting
Clinical Trials
9 trialsNCT02363400 2025-08-19
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
National Health Research Institutes, Taiwan
Phase 3 Terminated
NCT04832607 2025-07-18
TRACE
University Hospital Freiburg
Phase 3 Recruiting
NCT02578641 2023-06-28
VANCE
Tessa Therapeutics
Phase 3 Completed
NCT05775705 2023-03-20
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital
Phase 3 Not yet recruiting
NCT04084626 2022-01-05
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Beijing Friendship Hospital
Phase 3 Unknown
NCT02912702 2016-09-23
L-DEP as an Initial Treatment for EBV-HLH
Beijing Friendship Hospital
Phase 3 Unknown
NCT02631109 2016-08-04
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
Beijing Friendship Hospital
Phase 3 Unknown
NCT00129584 2009-08-18
Endobronchial Valve for Emphysema Palliation Trial (VENT)
Emphasys Medical
Phase 3 Completed